NASDAQ: MISTMilestone Pharmaceuticals Inc Stock
$1.27+0.05 (+4.1%)
Updated Jun 11, 2026
MIST Price
$1.27
Fair Value Price
$0.17
Market Cap
$158.11M
52 Week Low
$1.00
52 Week High
$3.06
P/E
-1.9x
P/B
4.39x
P/S
86.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.78M
Earnings
-$68.36M
Gross Margin
99.2%
Operating Margin
-3,437.5%
Profit Margin
-3,832%
Debt to Equity
4.37
Operating Cash Flow
-$51M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MIST Overview
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MIST's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MIST
Ranked#423 of 463
Ranked#423 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important MIST news, forecast changes, insider trades & much more!
MIST News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MIST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIST ($1.27) is overvalued by 660.54% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MIST ($1.27) is not significantly undervalued (660.54%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MIST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MIST due diligence checks available for Premium users.
Valuation
MIST fair value
Fair Value of MIST stock based on Discounted Cash Flow (DCF)
Price
$1.27
Fair Value
$0.17
Overvalued by
660.54%
MIST ($1.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MIST ($1.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MIST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MIST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.9x
Industry
17.66x
Market
13.95x
MIST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.39x
Industry
4.83x
MIST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIST's financial health
Profit margin
Revenue
$238.0k
Net Income
-$26.1M
Profit Margin
-10,952.1%
MIST's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MIST's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$193.7M
Liabilities
$157.7M
Debt to equity
4.37
MIST's short-term assets ($192.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIST's short-term assets ($192.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIST's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MIST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.1M
Investing
-$80.0M
Financing
$94.4M
MIST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MIST vs Biotech Stocks
Milestone Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.